Midi Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series D (Feb 2026) at $1B unicorn valuation. 230K+ patients in 50 states. Digital health's first menopause-focused unicorn. Expanding to longevity and cardiology.
About
Midi Health became digital health's first menopause-focused unicorn in February 2026, raising $100 million in Series D financing at a $1 billion valuation. The company serves 230,000+ patients across all 50 states with clinician-led care for menopause, perimenopause, and midlife women's health — a market that has been systematically underserved by mainstream healthcare despite affecting 50 million American women.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.